Form 4: Xenon Director Gillian Cannon Increases Stake

Xenon Pharmaceuticals Director Gillian Cannon reported the vesting of restricted share units and the grant of new stock options and RSUs, increasing her beneficial ownership.

Summary

• Gillian Cannon, a Director of Xenon Pharmaceuticals Inc. (XENE), reported changes in her beneficial ownership.
• On June 1, 2026, 2,645 Common Shares were acquired due to the vesting of a restricted share unit (RSU) award granted on June 5, 2025.
• The RSU award vested 100% on June 1, 2026, the day before the issuer's 2026 annual meeting of shareholders.
• On June 3, 2026, 10,507 Share Options (Right to Buy) were acquired with an exercise price of $53.46.
• These Share Options will vest 100% on the earlier of June 1, 2027, or the day before the issuer's 2027 annual meeting of shareholders.
• Also on June 3, 2026, 1,593 Restricted Share Units were acquired.
• Each RSU represents a contingent right to receive one Common Share, vesting 100% on the earlier of June 1, 2027, or the day before the issuer's 2027 annual meeting of shareholders.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively as it indicates a director's increased beneficial ownership and continued alignment with shareholder interests through the vesting of existing awards and the grant of new equity compensation.

Positives

• A Director, Gillian Cannon, increased her direct beneficial ownership of Common Shares by 2,645 through the vesting of RSUs.
• The grant of new stock options (10,507) and restricted share units (1,593) further aligns the Director's interests with those of shareholders, indicating continued commitment to the company's future performance.

Future Outlook

The Director's future beneficial ownership is set to increase further upon the vesting of the newly granted 10,507 Share Options and 1,593 Restricted Share Units, which are scheduled to vest on the earlier of June 1, 2027, or the day before the issuer's 2027 annual meeting of shareholders.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those involving acquisitions of company stock or equity awards by directors, are often viewed positively by the market as they signal confidence in the company's future prospects. In the biotechnology and pharmaceutical industry, where long-term development cycles are common, such commitments from leadership can be particularly reassuring.

Stakeholder Impact

• Shareholders: The increase in a director's beneficial ownership and future equity awards can be seen as a positive signal, potentially boosting investor confidence and aligning management incentives with shareholder value creation.

Next Steps

• Vesting of 10,507 Share Options on the earlier of June 1, 2027, or the day before the 2027 annual meeting of shareholders.
• Vesting of 1,593 Restricted Share Units on the earlier of June 1, 2027, or the day before the 2027 annual meeting of shareholders.

Key Dates

Keywords

Xenon Pharmaceuticals, XENE, Insider Transaction, Form 4, Director Ownership, Restricted Share Units, Stock Options, Equity Compensation, Beneficial Ownership